drugset
drugset / Trial / NCT00902772

Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users

NCT00902772 ↗

Phase 1 Completed 100 enrolled AstraZeneca
RandomizedCrossoverDouble-blind

Summary

The purpose of this study is to examine the abuse potential of AZD7325.

Timeline

Start
2009-05
Primary completion
—
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7325 Small molecule — Oral
Comparator Lorazepam Small molecule — Oral

Indications

No indication recorded.